Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy

Abstract The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe3 O4 (SHMNPs) core and a shell of aqueous stable self-doped poly[ N -(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubic...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials 2011-12, Vol.32 (34), p.8999-9010
Main Authors: Hua, Mu-Yi, Yang, Hung-Wei, Liu, Hao-Li, Tsai, Rung-Ywan, Pang, See-Tong, Chuang, Kun-Lung, Chang, Yu-Sun, Hwang, Tsong-Long, Chang, Ying-Hsu, Chuang, Heng-Chang, Chuang, Cheng-Keng
Format: Article
Language:English
Subjects:
Advanced Basic Science
Aniline Compounds - chemistry
Animals
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - pharmacokinetics
Antibiotics, Antineoplastic - pharmacology
Assessments
Bladder cancer
Cell Line, Tumor
Contrast agents
Contrast Media - chemistry
Dentistry
Doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - pharmacokinetics
Doxorubicin - pharmacology
Drug Delivery Systems - methods
Drugs
Ferrosoferric Oxide - chemistry
Humans
Magnetic resonance image
Magnetic Resonance Imaging - methods
Magnetic targeting therapy
Magnets - chemistry
Mice
Nanocomposites
Nanomaterials
Nanostructure
Nanostructures - chemistry
Nanostructures - ultrastructure
P-glycoprotein pump
Superhigh-magnetization nanocarriers
Therapy
Urinary Bladder Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe3 O4 (SHMNPs) core and a shell of aqueous stable self-doped poly[ N -(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug’s thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM−1 s−1 ) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.
ISSN:0142-9612
1878-5905
DOI:10.1016/j.biomaterials.2011.08.014